Acción MY00 KETAMINEONE CAPITAL
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas KetamineOne Capital Deutsche Boerse AG

Acciones

MY00

CA4925531028

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Wellbeing Digital Subsidiary KGK Science to Participate at the Mushroom Summit and Psychedelic Science Conference
Wellbeing Digital Enters into Share Purchase Agreement with Cardinal Group
Cardinal Group Companies LLC entered into an agreement to acquire KGK Science Inc. from Wellbeing Digital Sciences Inc. for $2 million.
Wellbeing Digital Subsidiary KGK Science to Participate at the Nutrition Industry Association Spring Conference
Wellbeing Subsidiary KGK Science Announces Successful Results of UP360, a Nutraceutical Ingredient Demonstrating Beneficial Immune Defense Response
Wellbeing Digital Sciences Inc.'s Wholly Owned Subsidiary KGK Sciences Inc Begins Recruitment in First-Of-Its-Kind Health Canada Approved Psilocybin Trial
Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial
Wellbeing Subsidiary KGK Science Receives Institutional Review Board Approval
Wellbeing Announces Cease Trade Order
IIROC Trading Halt - MEDI
Wellbeing Provides Bi-Weekly Default Status Report
Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference
Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion
Wellbeing Digital to Participate in The Global Biomedical Design Conference
Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout
Wellbeing Provides Bi-Weekly Default Status Report
Wellbeing Digital to Participate in MarigoldLIVE: International Women’s Day Networking Event
Wellbeing Provides Bi-Weekly Default Status Report
Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.
Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción MEDI
  4. Acción MY00
  5. Noticias KetamineOne Capital
  6. Otros idiomas